AU2006207999A1 - Leader sequences for directing secretion of polypeptides and methods for production thereof - Google Patents

Leader sequences for directing secretion of polypeptides and methods for production thereof Download PDF

Info

Publication number
AU2006207999A1
AU2006207999A1 AU2006207999A AU2006207999A AU2006207999A1 AU 2006207999 A1 AU2006207999 A1 AU 2006207999A1 AU 2006207999 A AU2006207999 A AU 2006207999A AU 2006207999 A AU2006207999 A AU 2006207999A AU 2006207999 A1 AU2006207999 A1 AU 2006207999A1
Authority
AU
Australia
Prior art keywords
protein
cell
polypeptide
sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006207999A
Other languages
English (en)
Inventor
Elizabeth Bosch
Robert Forgan Halenbeck
Ernestine Lee
Thomas Linnemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Prime Therapeutics Inc
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of AU2006207999A1 publication Critical patent/AU2006207999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2006207999A 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof Abandoned AU2006207999A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64701305P 2005-01-27 2005-01-27
US60/647,013 2005-01-27
PCT/US2006/002951 WO2006081430A2 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Publications (1)

Publication Number Publication Date
AU2006207999A1 true AU2006207999A1 (en) 2006-08-03

Family

ID=36741080

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006207999A Abandoned AU2006207999A1 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Country Status (9)

Country Link
US (1) US20080286834A1 (https=)
EP (1) EP1841874B1 (https=)
JP (2) JP2008528033A (https=)
AT (1) ATE454455T1 (https=)
AU (1) AU2006207999A1 (https=)
CA (1) CA2589895A1 (https=)
DE (1) DE602006011574D1 (https=)
DK (1) DK1841874T3 (https=)
WO (1) WO2006081430A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
US9060961B2 (en) * 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2009056330A1 (en) * 2007-10-31 2009-05-07 Eth Zurich Soluble truncated apom proteins and medical uses thereof
EP2271358B1 (en) * 2008-03-25 2018-11-21 Amarantus Therapeutics, Inc. use of mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
WO2010075194A1 (en) * 2008-12-22 2010-07-01 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active dkk
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
DK2585098T3 (da) 2010-06-28 2014-11-03 Five Prime Therapeutics Inc Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
KR101910779B1 (ko) 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Fgfr1 세포밖 도메인 조합치료
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
AU2012205384B2 (en) 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
EP2858679B2 (en) 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP4331620A3 (en) 2012-12-07 2024-12-04 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery
EP2970940B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
KR102516152B1 (ko) 2013-08-01 2023-03-31 파이브 프라임 테라퓨틱스, 인크. 비푸코실화된 항-fgfr2iiib 항체
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP3212670B1 (en) 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
MX2017008218A (es) 2014-12-22 2017-10-18 Five Prime Therapeutics Inc Anticuerpos anti-csf1r para tratar pvns.
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
AU2016249981B2 (en) 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
AU2016342269A1 (en) 2015-10-22 2018-03-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
ES2981471T3 (es) 2016-04-25 2024-10-09 Five Prime Therapeutics Inc NOPE para el tratamiento de la pérdida de masa muscular y la debilidad muscular patológicas
HRP20211703T1 (hr) 2016-11-02 2022-02-04 Jounce Therapeutics, Inc. Protutijela protiv pd-1 i njihova upotreba
CN109906030B (zh) 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
TWI685351B (zh) * 2016-12-29 2020-02-21 財團法人生物技術開發中心 延長蛋白質藥物體內半衰期的激肽原-1衍生胜肽
CN110709420A (zh) 2017-03-31 2020-01-17 戊瑞治疗有限公司 使用抗gitr抗体的癌症组合疗法
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
AU2018281334A1 (en) 2017-06-06 2019-12-19 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use
EA202091540A1 (ru) 2017-12-22 2021-03-22 Джаунс Терапьютикс, Инк. Антитела к lilrb2
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
US20220112257A1 (en) * 2019-01-11 2022-04-14 Arbele Limited Mul tispecific prochemokine therapeutic proteins (park) and method of making and using thereof
US20220152098A1 (en) 2019-03-01 2022-05-19 Achelois Biopharma, Inc. Methods of modulating cd160 function in the antigen-specific immune cell and uses thereof
WO2021178001A1 (en) * 2020-03-05 2021-09-10 Curie Co. Inc. Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN116724051A (zh) 2020-08-10 2023-09-08 上海寻百会生物技术有限公司 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712114A (en) * 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
DK1105508T3 (da) * 1998-08-17 2003-01-06 Europ Lab Molekularbiolog Fremgangsmåde til oprensning af biomolekyle- eller proteinkomplekser
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
EP2479277B1 (en) * 2004-07-22 2015-09-02 Five Prime Therapeutics, Inc. Use of MGD-CSF in a method of treatment of Alzheimer's disease.

Also Published As

Publication number Publication date
WO2006081430A2 (en) 2006-08-03
EP1841874A2 (en) 2007-10-10
US20080286834A1 (en) 2008-11-20
JP2009131268A (ja) 2009-06-18
EP1841874B1 (en) 2010-01-06
CA2589895A1 (en) 2006-08-03
WO2006081430A9 (en) 2006-11-30
JP2008528033A (ja) 2008-07-31
WO2006081430A3 (en) 2007-04-05
DK1841874T3 (da) 2010-05-17
DE602006011574D1 (de) 2010-02-25
ATE454455T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
AU2006207999A1 (en) Leader sequences for directing secretion of polypeptides and methods for production thereof
CN112375784B (zh) 制备重组新型冠状病毒Spike蛋白的方法
JP2003527072A (ja) 蛋白質ライブラリーに関する蛋白質設計オートメーション
US20230383276A1 (en) Process for making recombinant antidote to factor xa inhibitor
CN107001438A (zh) 白细胞介素‑15组合物及其用途
EP2486132A1 (en) Combinatorial libraries based on c-type lectin domain
CN119895043A (zh) 一种转座子系统及其应用
CN105524147B (zh) 重组聚多肽及其应用
CN120659875A (zh) 一种转座酶、转座子、转座子系统及其应用
AU2003284260B2 (en) Production of homotrimeric fusion proteins
US20090029907A1 (en) Recombinant Method for Production of an Erythropoiesis Stimulating Protein
US6933364B1 (en) Secretory thyroid stimulating hormone receptor, and method for assaying anti-thyroid stimulating hormone receptor antibody using the same
WO2010001414A1 (en) Expression of heterologous proteins in bacterial system using a gm-csf fusion tag
WO2018076008A1 (en) Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins
WO2020139855A2 (en) Chimeric signal peptides for protein production
CN101511866A (zh) 经修饰的人类血浆多肽或Fc骨架和其用途
CN119506295B (zh) 一种前列腺特异性膜抗原的制备方法
CN121851181A (zh) 一种基于模块化蛋白的融合蛋白及其应用
KR101174494B1 (ko) 인간 과립구 콜로니 자극인자의 생물학적 활성 증가 변이체
HK40041902A (en) Method for preparing a recombinant novel coronavirus spike protein
JP2013055935A (ja) タンパク質の製造方法
CA2389383A1 (en) Educational kit and method containing novel alpha helical protein-34
WO2002098908A9 (en) Osteoclastogenesis inhibitory factor, sequence coding for it and uses

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application